Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Arthur Website

Larry O. Arthur, Ph.D.

Selected Publications
1)  Banks WA, Kumar VB, Franko MW, Bess JW, Arthur LO.
Evidence that the species barrier of human immunodeficiency virus-1 does not extend to uptake by the blood--brain barrier: comparison of mouse and human brain microvessels.
Life Sci. 77: 2361-8, 2005. [Journal]
2)  Crise B, Li Y, Yuan C, Morcock DR, Whitby D, Munroe DJ, Arthur LO, Wu X.
Simian immunodeficiency virus integration preference is similar to that of human immunodeficiency virus type 1.
J. Virol. 79: 12199-204, 2005. [Journal]
3)  Banks WA, Robinson SM, Wolf KM, Bess JW, Arthur LO.
Binding, internalization, and membrane incorporation of human immunodeficiency virus-1 at the blood-brain barrier is differentially regulated.
Neuroscience. 128: 143-53, 2004. [Journal]
4)  Lifson JD, Rossio JL, Piatak M, Bess J, Chertova E, Schneider DK, Coalter VJ, Poore B, Kiser RF, Imming RJ, Scarzello AJ, Henderson LE, Alvord WG, Hirsch VM, Benveniste RE, Arthur LO.
Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins.
AIDS Res. Hum. Retroviruses. 20: 772-87, 2004. [Journal]
5)  Graham DR, Chertova E, Hilburn JM, Arthur LO, Hildreth JE.
Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts.
J. Virol. 77: 8237-48, 2003. [Journal]
6)  Willey RL, Byrum R, Piatak M, Kim YB, Cho MW, Rossio Jr JL, Bess Jr J, Igarashi T, Endo Y, Arthur LO, Lifson JD, Martin MA.
Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles.
J Virol. 77: 1163-74, 2003. [Journal]
7)  Zhu P, Chertova E, Bess J, Lifson JD, Arthur LO, Liu J, Taylor KA, Roux KH.
Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.
Proc. Natl. Acad. Sci. U.S.A. 100: 15812-7, 2003. [Journal]
8)  Chertova E, Bess Jr JW, Crise BJ, Sowder II RC, Schaden TM, Hilburn JM, Hoxie JA, Benveniste RE, Lifson JD, Henderson LE, Arthur LO.
Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.
J Virol. 76: 5315-25, 2002. [Journal]
9)  Center RJ, Leapman RD, Lebowitz J, Arthur LO, Earl PL, Moss B.
Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface.
J Virol. 76: 7863-7, 2002. [Journal]
10)  Lifson JD, Piatak M, Rossio JL, Bess J, Chertova E, Schneider D, Kiser R, Coalter V, Poore B, Imming R, Desrosiers RC, Henderson LE, Arthur LO.
Whole inactivated SIV virion vaccines with functional envelope glycoproteins: safety, immunogenicity, and activity against intrarectal challenge.
J Med Primatol. 31: 205-16, 2002. [Journal]
11)  Esser MT, Graham DR, Coren LV, Trubey CM, Bess JW, Arthur LO, Ott DE, Lifson JD.
Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation.
J Virol. 75: 6173-82, 2001. [Journal]
12)  Buseyne F, Le Gall S, Boccaccio C, Abastado JP, Lifson JD, Arthur LO, Rivière Y, Heard JM, Schwartz O.
MHC-I-restricted presentation of HIV-1 virion antigens without viral replication.
Nat Med. 7: 344-9, 2001. [Journal]
13)  Center RJ, Schuck P, Leapman RD, Arthur LO, Earl PL, Moss B, Lebowitz J.
Oligomeric structure of virion-associated and soluble forms of the simian immunodeficiency virus envelope protein in the prefusion activated conformation.
Proc Natl Acad Sci U S A. 98: 14877-82, 2001. [Journal]
14)  Esser MT, Bess JW, Suryanarayana K, Chertova E, Marti D, Carrington M, Arthur LO, Lifson JD.
Partial activation and induction of apoptosis in CD4(+) and CD8(+) T lymphocytes by conformationally authentic noninfectious human immunodeficiency virus type 1.
J Virol. 75: 1152-64, 2001. [Journal]
15)  Gorelick RJ, Lifson JD, Yovandich JL, Rossio JL, Piatak M, Scarzello AJ, Knott WB, Bess JW, Fisher BA, Flynn BM, Henderson LE, Arthur LO, Benveniste RE.
Mucosal challenge of Macaca nemestrina with simian immunodeficiency virus (SIV) following SIV nucleocapsid mutant DNA vaccination.
J Med Primatol. 29: 209-19, 2000. [Journal]
16)  Gorelick RJ, Benveniste RE, Lifson JD, Yovandich JL, Morton WR, Kuller L, Flynn BM, Fisher BA, Rossio JL, Piatak M, Bess JW, Henderson LE, Arthur LO.
Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost.
J Virol. 74: 11935-49, 2000. [Journal]

This page was last updated on 7/25/2006.